Evolving Standard Of Care May Be To Blame For Phase III Failure Of Ulimorelin, Tranzyme Says
This article was originally published in Pharmaceutical Approvals Monthly
An evolution in the methods hospitals use to speed gastrointestinal recovery after abdominal surgery may have undercut the Phase III efficacy results for the intravenous ghrelin agonist, which was shown to be no better than placebo in the first of two pivotal trials to report.
You may also be interested in...
Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug
Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.
FDA’s Strongest REMS To Date: Entereg Approved With Controlled-Distribution
Adolor and marketing partner GlaxoSmithKline's post-operative constipation therapy Entereg is the first drug to clear FDA with its highest level of Risk Evaluation and Mitigation Strategy - a required controlled distribution program. Entereg is at least the fifth new drug, and the second new molecular entity, to be approved with a REMS since the new authority granted by the FDA Amendments Act went into effect March 25
At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion
Agency’s presentations on Biogen/Ionis’ ALS drug included differing viewpoints from the statistical and clinical pharmacology teams; the transparency and emphasis on a multidisciplinary review approach may reflect lessons learned from missteps at the Aduhelm panel review in 2020.